Unichem Laboratories Limited
NSE: UNICHEMLAB BSE: UNICHEMLAB
NSE
590.85
-6.55 (-1.10%)
Prev Close
597.4
Open Price
597.4
Volume
17,355
Today Low / High
588 / 601.45
52 WK Low / High
511.55 / 937.95
Range
561 - 620
BSE
590.55
-7.85 (-1.31%)
Prev Close
598.4
Open Price
610
Volume
859
Today Low / High
588.4 / 610
52 WK Low / High
512.9 / 949.85
Range
561 - 620
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 590.85 (target range: 561 - 620), reflecting a change of -6.55 (-1.09642%). On the BSE, it is listed at 590.55 (target range: 561 - 620), showing a change of -7.85 (-1.31183%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
11 Jul
597.40
-1.10%
10 Jul
605.05
-1.26%
09 Jul
600.05
0.83%
08 Jul
601.40
-0.39%
07 Jul
597.00
0.74%
04 Jul
586.20
1.65%
03 Jul
587.10
-0.49%
02 Jul
594.20
-1.19%
01 Jul
594.60
-0.07%
30 Jun
591.90
-0.44%
27 Jun
600.00
-1.35%
26 Jun
602.70
-0.46%
25 Jun
590.95
1.57%
24 Jun
589.85
0.19%
23 Jun
577.55
2.01%
20 Jun
570.15
2.84%
19 Jun
578.00
-1.36%
18 Jun
594.80
-3.48%
17 Jun
606.00
-2.67%
16 Jun
606.95
-0.87%
Unichem Laboratories Limited Graph
Unichem Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Unichem Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 590.85, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 590.55 | 596.46 | 536.81 - 656.10 |
| 602.36 | 481.89 - 722.83 | ||
| 608.27 | 425.79 - 790.75 | ||
| Bearish Scenario | 590.55 | 584.64 | 526.18 - 643.11 |
| 578.74 | 462.99 - 694.49 | ||
| 572.83 | 400.98 - 744.68 |
Overview of Unichem Laboratories Limited
ISIN
INE351A01035
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
71,264
Market Cap
41,599,266,930
Last Dividend
0
Official Website
IPO Date
2002-07-01
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of UNICHEMLAB
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2022-08-01 | August 01, 22 | 4 | 4 | 2022-08-02 | 2022-08-20 | |
| 2021-07-22 | July 22, 21 | 4 | 4 | 2021-07-24 | 2021-08-30 | |
| 2020-08-20 | August 20, 20 | 4 | 4 | 2020-08-22 | 2020-09-04 | |
| 2019-07-18 | July 18, 19 | 4 | 4 | 2019-07-20 | 2019-08-02 | |
| 2018-07-19 | July 19, 18 | 5 | 5 | 2018-07-21 | 2018-08-03 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,110.97 Cr | 863.67 Cr | 1,247.30 Cr | 0.5909 | 0.00 Cr | 0.00 Cr | 845.09 Cr | 137.52 Cr | 19.53 | 264.86 Cr | 0.0651 |
| 2024-03-31 | 1,657.42 Cr | 1,339.98 Cr | 317.43 Cr | 0.1915 | 104.67 Cr | 43.29 Cr | -12.99 Cr | -70.47 Cr | -10.01 | 74.24 Cr | -0.0425 |
| 2023-03-31 | 1,343.02 Cr | 550.93 Cr | 792.10 Cr | 0.5898 | 26.39 Cr | 33.32 Cr | -150.61 Cr | -202.23 Cr | -28.73 | -46.67 Cr | -0.1506 |
| 2022-03-31 | 1,247.98 Cr | 440.54 Cr | 807.44 Cr | 0.6470 | 33.76 Cr | 32.48 Cr | -11.14 Cr | 33.06 Cr | 4.70 | 118.22 Cr | 0.0265 |
| 2021-03-31 | 1,189.92 Cr | 401.37 Cr | 788.55 Cr | 0.6627 | 43.90 Cr | 36.42 Cr | 7.28 Cr | 34.32 Cr | 4.88 | 141.23 Cr | 0.0288 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 117.63 Cr | 3,569.40 Cr | 1,118.81 Cr | 2,450.5900 Cr | 459.77 Cr | 342.14 Cr | 988.74 Cr | 1,309.99 Cr | 0.00 Cr | 0.00 Cr | 0.02 Cr | 994.3100 Cr |
| 2024-03-31 | 150.91 Cr | 3,169.34 Cr | 806.93 Cr | 2,362.4188 Cr | 247.51 Cr | 96.60 Cr | 704.68 Cr | 1,324.21 Cr | 7.69 Cr | 0.87 Cr | -1.32 Cr | 707.8787 Cr |
| 2023-03-31 | 183.75 Cr | 3,193.05 Cr | 757.74 Cr | 2,435.3041 Cr | 314.05 Cr | 130.29 Cr | 625.23 Cr | 1,402.57 Cr | 58.12 Cr | 1.10 Cr | 1.62 Cr | 639.6008 Cr |
| 2022-03-31 | 109.20 Cr | 3,318.77 Cr | 700.36 Cr | 2,618.4110 Cr | 349.15 Cr | 239.96 Cr | 600.22 Cr | 1,482.30 Cr | 70.72 Cr | 4.69 Cr | -260.62 Cr | 552.1277 Cr |
| 2021-03-31 | 77.46 Cr | 3,125.71 Cr | 568.88 Cr | 2,556.8348 Cr | 119.09 Cr | 41.63 Cr | 538.34 Cr | 1,446.37 Cr | 134.27 Cr | 4.69 Cr | -80.84 Cr | 505.7611 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -7.0200 Cr | -241.2300 Cr | 183.7600 Cr | -144.3800 Cr | -61.3324 Cr | 89.5800 Cr | -137.3600 Cr | 137.5200 Cr | 18.8300 Cr | -0.3400 Cr | -252.4800 Cr |
| 2024-03-31 | 16.6940 Cr | 50.4043 Cr | -106.3113 Cr | -5.8533 Cr | -32.8398 Cr | 150.9124 Cr | -22.5473 Cr | -70.4743 Cr | -78.4796 Cr | -0.2135 Cr | -79.4469 Cr |
| 2023-03-31 | -85.0907 Cr | 202.8133 Cr | -81.2999 Cr | -129.4064 Cr | 74.5559 Cr | 183.7522 Cr | -44.3157 Cr | -176.3629 Cr | -33.3557 Cr | -28.2545 Cr | -25.0078 Cr |
| 2022-03-31 | -259.6120 Cr | 100.1193 Cr | 191.2282 Cr | -386.6144 Cr | 31.7355 Cr | 109.1963 Cr | -127.0024 Cr | 21.9689 Cr | 109.8250 Cr | -28.3615 Cr | -61.8817 Cr |
| 2021-03-31 | 33.0987 Cr | -73.5576 Cr | -121.1911 Cr | -254.7157 Cr | -154.0576 Cr | 77.4608 Cr | -287.8144 Cr | 51.4794 Cr | -83.4086 Cr | -28.6579 Cr | -141.7988 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 587.18 Cr | 264.57 Cr | 322.61 Cr | 0.5494 | 226.14 Cr | 52.97 Cr | 7.52 | 85.15 Cr | 0.0902 |
| 2024-12-31 | 533.09 Cr | 191.52 Cr | 341.57 Cr | 0.6407 | 54.98 Cr | 57.85 Cr | 8.22 | 99.14 Cr | 0.1085 |
| 2024-09-30 | 462.16 Cr | 174.48 Cr | 287.68 Cr | 0.6225 | 28.99 Cr | 30.49 Cr | 4.34 | 66.32 Cr | 0.0660 |
| 2024-06-30 | 446.43 Cr | 287.39 Cr | 159.04 Cr | 0.3562 | 161.65 Cr | 9.26 Cr | 1.31 | 43.50 Cr | 0.0207 |
| 2024-03-31 | 431.70 Cr | 293.47 Cr | 138.23 Cr | 0.3202 | -127.43 Cr | -129.31 Cr | -18.37 | -94.12 Cr | -0.2995 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 117.63 Cr | 0.00 Cr | 117.63 Cr | 778.81 Cr | 988.74 Cr | 2,037.95 Cr | 1,309.99 Cr | 3,569.40 Cr | 1,118.81 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 198.03 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,400.65 Cr |
| 2024-09-30 | 187.78 Cr | 10.64 Cr | 198.42 Cr | 0.00 Cr | 837.46 Cr | 1,823.47 Cr | 1,296.43 Cr | 3,310.96 Cr | 910.31 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 152.25 Cr | 0.00 Cr | 0.00 Cr | 152.25 Cr | 0.00 Cr | 0.00 Cr | -2,362.42 Cr |
| 2024-03-31 | 154.32 Cr | 1.34 Cr | 155.66 Cr | 619.10 Cr | 704.68 Cr | 1,694.16 Cr | 1,317.14 Cr | 3,169.34 Cr | 806.93 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 52.97 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 57.85 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 30.49 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 9.26 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | -129.31 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2010-10-21 | October 21, 10 | 5:2 |
| 2004-03-16 | March 16, 04 | 2:1 |
| 2001-07-03 | July 03, 01 | 2:1 |
| 2000-04-03 | April 03, 00 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,672.00 | ₹4,011,596,160,000.00 | ₹1,298,300.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,835.00 | ₹1,814,480,615,000.00 | ₹224,031.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,314.20 | ₹1,121,674,419,000.00 | ₹344,196.00 |
| Mankind Pharma Limited | MANKIND | ₹2,578.30 | ₹1,064,138,561,908.00 | ₹2,780,363.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,254.70 | ₹1,044,010,449,778.00 | ₹895,308.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹979.60 | ₹985,702,908,000.00 | ₹921,030.00 |
| Lupin Limited | LUPIN | ₹1,894.70 | ₹865,339,805,200.00 | ₹1,511,045.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,124.80 | ₹653,286,089,600.00 | ₹1,058,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,181.10 | ₹615,508,601,100.00 | ₹15,678,334.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,806.70 | ₹574,713,085,500.00 | ₹183,070.00 |
| Laurus Labs Limited | LAURUSLABS | ₹790.20 | ₹426,117,720,600.00 | ₹1,475,669.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,017.95 | ₹389,434,085,794.00 | ₹322,114.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,449.60 | ₹367,769,318,400.00 | ₹119,065.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,626.50 | ₹328,081,368,000.00 | ₹236,895.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,757.10 | ₹285,491,850,900.00 | ₹3,159,181.00 |
| Piramal Enterprises Limited | PEL | ₹1,217.50 | ₹275,980,465,000.00 | ₹2,508,249.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,608.60 | ₹251,036,507,400.00 | ₹444,444.00 |
| Eris Lifesciences Limited | ERIS | ₹1,709.80 | ₹232,869,630,600.00 | ₹106,770.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,241.50 | ₹231,037,500,000.00 | ₹20,847.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹976.60 | ₹191,963,425,800.00 | ₹60,016.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,165.70 | ₹185,673,861,700.00 | ₹144,076.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹961.80 | ₹172,267,998,000.00 | ₹1,353,979.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,301.00 | ₹157,820,599,900.00 | ₹74,663.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,023.30 | ₹153,794,472,610.00 | ₹35,929.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹469.00 | ₹113,800,036,000.00 | ₹331,193.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,755.50 | ₹95,537,846,700.00 | ₹23,112.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹896.75 | ₹87,693,989,575.00 | ₹154,034.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹927.20 | ₹84,036,419,664.00 | ₹291,915.00 |
| Strides Pharma Science Limited | STAR | ₹887.80 | ₹81,822,045,060.00 | ₹428,094.00 |
| FDC Limited | FDC | ₹501.35 | ₹81,624,793,500.00 | ₹72,209.00 |
| Suven Life Sciences Limited | SUVEN | ₹276.63 | ₹60,325,810,620.00 | ₹285,602.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹159.34 | ₹51,709,335,480.00 | ₹1,252,722.00 |
| Innova Captab Limited | INNOVACAP | ₹875.40 | ₹50,094,703,722.00 | ₹46,543.00 |
| Sequent Scientific Limited | SEQUENT | ₹184.32 | ₹46,136,217,600.00 | ₹343,582.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹473.60 | ₹43,225,472,000.00 | ₹158,284.00 |
| Hikal Limited | HIKAL | ₹340.50 | ₹41,983,990,500.00 | ₹164,468.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,526.20 | ₹41,780,821,800.00 | ₹17,230.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹590.85 | ₹41,599,266,930.00 | ₹17,355.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.30 | ₹36,431,529,530.00 | ₹55,088.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.05 | ₹35,002,035,900.00 | ₹50,065.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹62.67 | ₹34,340,277,180.00 | ₹1,978,828.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹664.85 | ₹32,014,522,050.00 | ₹589,436.00 |
| Indoco Remedies Limited | INDOCO | ₹326.45 | ₹30,114,326,955.00 | ₹174,646.00 |
| Alembic Limited | ALEMBICLTD | ₹117.26 | ₹30,110,257,203.00 | ₹332,328.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹91.18 | ₹26,763,791,860.00 | ₹1,225,212.00 |
Key Executives
Chief Manufacturing & Compliance Officer
Dr. Ashwani Kumar
Gender: Not Specified
Year Born:
Chief Executive of Domestic Pharma
Mr. Bhagwat S. Dhingra
Gender: male
Year Born: 1963
Chief Quality & Compliance Officer
Mr. Jalesh Burye
Gender: male
Year Born:
MD & Director
Mr. Pabitra Kumar Kalipada Bhattacharya
Gender: male
Year Born: 1969
Head of Legal, Company Secretary & Compliance Officer
Mr. Pradeep Kumar Bhandari
Gender: male
Year Born: 1958
Vice President of Chemical of Research and Development
Dr. P. B. Deshpande M.Sc. Ph.D.
Gender: Not Specified
Year Born: 1955
Vice President of Human Resources & ER
Mr. Prasad Joshi
Gender: male
Year Born: 1958
President of North America & Chief Executive Officer of North America
Mr. Scott B. Delaney
Gender: male
Year Born: 1969
Chief Scientific & Compliance Officer
Dr. Dhananjay Sathe
Gender: Not Specified
Year Born:
Head of Projects & Investments
Mr. Vinod Kumar Behl
Gender: male
Year Born: 1950
FAQs about Unichem Laboratories Limited
Who is the CEO of the company?
The CEO is Scott B. Delaney.
What is the current market price of the stock?
The current price is ₹590.85.
What is the 52-week price range?
The range is ₹511.55-937.95.
What is the market capitalization of the company?
The market capitalization is ₹4,159.93 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 27.72.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Unichem Laboratories Limited (ISIN: INE351A01035) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹4,159.93 crores and an average daily volume of 71,264 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.